{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:27Z","timestamp":1786991967392,"version":"build-2736575974"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdcr.2024.06.033","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:09:39Z","timestamp":1720444179000},"page":"97-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure"],"prefix":"10.1016","volume":"51","author":[{"given":"Alice","family":"Sohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Michael","family":"Lewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-0100","authenticated-orcid":false,"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2024.06.033_bib1","first-page":"348","article-title":"Use of JAK inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.jdcr.2024.06.033_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling","volume":"144","author":"Somani","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jdcr.2024.06.033_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2024.06.033_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.jdcr.2024.06.033_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2024.06.033_bib6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2024.06.033_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.jdcr.2024.06.033_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.jdcr.2024.06.033_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jdcr.2024.06.033_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.jdcr.2024.06.033_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy","volume":"62","author":"Amstad","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.jdcr.2024.06.033_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624002613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624002613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T08:01:15Z","timestamp":1726387275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624002613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":12,"alternative-id":["S2352512624002613"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.06.033","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}